Boston, Massachusetts 02115

  • Hyperaldosteronism

Purpose:

OBJECTIVES: I. Determine the prevalence of glucocorticoid-remediable aldosteronism (GRA) in various hypertensive populations and screen at risk members of GRA pedigrees. II. Investigate other factors regulating blood pressure in GRA (environmental, genetically determined factors). III. Investigate renal and hormonal mechanisms regulating potassium homeostasis in GRA. IV. Describe clinical phenotype of GRA patients. V. Prospectively screen GRA-affected patients with MRI angiography for intracranial aneurysm.


Study summary:

PROTOCOL OUTLINE: Patients are screened for high blood pressure, suppressed plasma renin activity level, and low potassium levels. Urine is collected for a 24 hour period. Blood specimen is collected for molecular biologic evaluation for the presence of the chimeric gene diagnostic of GRA. Any history of cardiovascular events is recorded.


Criteria:

PROTOCOL ENTRY CRITERIA: --Disease Characteristics-- Diagnosed glucocorticoid-remediable aldosteronism (GRA) with hypertension Hypokalemia is variably seen Blood pressure variably elevated Elevated level of aldosterone Low level of plasma renin activity


Study is Available At:


Original ID:

199/11917


NCT ID:

NCT00004354


Secondary ID:

BWH-91328603


Study Acronym:


Brief Title:

Study of Prevalence and Clinical Phenotype in Patients With Glucocorticoid-Remediable Aldosteronism


Official Title:


Overall Status:

Completed


Study Phase:

N/A


Genders:

Both


Minimum Age:

N/A


Maximum Age:

N/A


Quick Facts

Healthy Volunteers
Oversight Has DMC
Study Is FDA Regulated
Study Is Section 801
Has Expanded Access

Study Source:

National Center for Research Resources (NCRR)


Oversight Authority:

United States: Federal Government


Reasons Why Stopped:


Study Type:

Observational


Study Design:

Primary Purpose: Screening


Number of Arms:

0


Number of Groups:

0


Total Enrollment:

0


Enrollment Type:


Overall Contact Information

Official Name:Robert G. Dluhy
Study Chair
Brigham and Women's Hospital

Study Dates

Start Date:June 1999
Verification Date:May 2002
Last Changed Date:June 23, 2005
First Received Date:October 18, 1999

Study Outcomes

There are no available Study Outcomes

Study Interventions

There are no available Study Interventions

Study Arms

There are no available Study Arms

Study Agencies

Agency Class:NIH
Agency Type:Lead Sponsor
Agency Name:National Center for Research Resources (NCRR)
Agency Class:Other
Agency Type:Collaborator
Agency Name:Brigham and Women's Hospital

Sample and Retention Information

There are no available Sample and Retention Information

Study References

There are no available Study References

Data Source: ClinicalTrials.gov

Date Processed: July 27, 2021

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


This study is not currently recruiting Study Participants. The form below is not enabled.